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Abstract
Macrophage interaction with oxidized low-density lipoprotein (oxLDL) leads to its differentiation into foam cells and
cytokine production, contributing to atherosclerosis development. In a previous study, we showed that CD36 and the
receptor for platelet-activating factor (PAFR) are required for oxLDL to activate gene transcription for cytokines and
CD36. Here, we investigated the localization and physical interaction of CD36 and PAFR in macrophages stimulated
with oxLDL. We found that blocking CD36 or PAFR decreases oxLDL uptake and IL-10 production. OxLDL induces
IL-10 mRNA expression only in HEK293T expressing both receptors (PAFR and CD36). OxLDL does not induce
IL-12 production. The lipid rafts disruption by treatment with βCD reduces the oxLDL uptake and IL-10 production.
OxLDL induces co-immunoprecipitation of PAFR and CD36 with the constitutive raft protein flotillin-1, and
colocalization with the lipid raft-marker GM1-ganglioside. Finally, we found colocalization of PAFR and CD36 in
macrophages from human atherosclerotic plaques. Our results show that oxLDL induces the recruitment of PAFR
and CD36 into the same lipid rafts, which is important for oxLDL uptake and IL-10 production. This study provided
new insights into how oxLDL interact with macrophages and contributing to atherosclerosis development.
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Introduction
The oxidation of Low Density Lipoprotein (LDL) is a major
pathogenic factor in the development of atherosclerosis.
Oxidized LDL (oxLDL) accumulates in the sub-endothelial
space of the arterial wall and activates endothelial cells,
smooth muscle cells and macrophages. The resulting chronic
inflammatory response contributes to atherosclerotic plaque
progression[1]. Although is well accepted that the uptake of
oxLDL has pathophysiologic relevance in atherosclerosis
development, the molecular mechanisms of its interaction with
macrophages are not fully understood.
CD36 is one of the main scavenger receptors involved in the
uptake of oxLDL by macrophages and has generally been
viewed as essential for foam cell formation[2]. Its deficiency
greatly reduced the uptake of oxLDL and atherosclerotic
lesions in mice models[3,4]. Monocytes from individuals lacking
CD36, or in vitro experiments using functional blockage of this
receptor with antibodies, decreased the oxLDL uptake by 50%
[3]. However, other studies have found that a deficiency of
CD36 did not prevent macrophage foam cell formation in
vivo[5,6]. These contradictory observations suggest that
additional receptor(s) might be involved in macrophage
activation by oxLDL and foam cell formation.
The oxidative modification of LDL generates several oxidized
phospholipids (oxPL) that share a common unsaturated fatty
acid in the sn-2 position of the phosphatidylcholine and confer
the ability to bind to CD36[7]. These structural characteristics
are also responsible for the interaction of some oxPL with the
receptor for Platelet Activating Factor (PAFR) [8], which its
expression has been found in macrophages from human
atherosclerotic plaques[9]. In previous studies we
demonstrated that deficiency or antagonism of PAFR reduced
the oxLDL uptake by human macrophages and CD36
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expression. It was also found that co-stimulation of CD36 and
PAFR is required for IL-8 and MCP-1 production by
macrophages exposed to oxLDL[10,11]. We also showed that
oxLDL stimulates a number of signal transduction pathways
through PAFR engagement including MAPK and PI3K/Akt
pathway activation, which leads to the transcription of genes for
cytokines and CD36 as well[11]. Because CD36 has a very
short cytoplasmic domain[12], it has been suggested that its
association with other receptors is required for activating
intracellular signaling pathways[13,14].
The PAFR has, in its amino acid sequence, a binding motif
for caveolin-1[15], which is a constitutive protein in lipid raft
platforms. Thus, we hypothesized that the association of PAFR
with CD36 might occur in lipid raft domains. In the present
study, we found that oxLDL induces the formation of a complex
comprising CD36, PAFR and Flotillin-1 within lipid raft
platforms and this is required for the uptake of oxLDL and IL-10
production by macrophages. Moreover, we found colocalization
of PAFR and CD36 in human atherosclerotic plaques.
Materials and Methods
Purification and oxidation of LDL
The study was approved by the ethics committee of the
Institute of Biomedical Sciences, University of Sao Paulo and
the participants provide their written consent. Blood was
collected from normolipidemic volunteers and plasma was
obtained after centrifugation at 1,000 g, 4°C, for 15 min in the
presence of EDTA 1 mg/mL. Thereafter, we added
benzamidine (2 mmol/L), gentamicin (0.5%), chloramphenicol
(0.25%), PMSF (phenyl-methyl-sulfonyl-fluoride) (0.5 mmol/L),
and aprotinin (0.1 U/mL) (all acquired from Sigma-Aldrich, St.
Louis, MO, USA). LDL (density: 1.019-1.063 g/mL) was
isolated by sequential ultracentrifugation (100,000 g, 4°C),
using a P90AT-0132 rotor (CP70MX ultracentrifuge; Hitachi
Koki Co., Ltd, Tokyo, Japan), dialyzed (4°C) against PBS, pH
7.4 containing 1 mmol/L EDTA, filtered (0.22 μm) and stored at
4°C. The protein concentration was determined by the BCA kit
(Thermo Scientific, Rockford, IL, USA). Part of the LDL was
dialyzed overnight against EDTA-free PBS. The LDL with
minimal degree of oxidation (moxLDL) was obtained by dialysis
of LDL (2 mg/mL) against 2 μM FeSO4· 7H2O in PBS (pH 7.2)
for 48 h at room temperature in the dark. Highly oxidized LDL
(oxLDL) was obtained by incubation of LDL with CuSO4 (5
μmol/L per mg of LDL protein/ 18 h/ 37°C). The oxidation for
both methods was stopped by the addition of 1 mmol/L EDTA,
the degree of oxidation was determined by measuring the
concentration of tiobarbituric acid-reactive substances
(TBARS) and conjugated dienes. TBARS values for LDL,
moxLDL and oxLDL were 0.2, 7.5, and 53.1 nmol/mg protein
respectively. Conjugated dienes were mesured by optical
density at 234 nm: 2.84, 3.02, and 4.00 for LDL, moxLDL and
oxLDL respectively.
Cell culture
6–8 week old male C57BL/6 mice were obtained from our
own animal facilities and were housed in a room with 12 h
light–dark cycle with water and food ad libitum. Animal care
and research protocols were in accordance with the principles
and guidelines adopted by the Brazilian College of Animal
Experimentation (COBEA) and approved by the Biomedical
Sciences Institute/USP—Ethical Committee for Animal
Research (CEEA). We did not perform in vivo studies. Bone
marrow-derived macrophages (BMDM) were established as
previously described by Davies and Gordon (2005)[16], with
minor modifications. In brief, femurs were flushed with PBS,
using a 26 x 1.2”-gauge needle. Cells were grown in L-Cell
conditioned medium (DMEM containing 20% L929 cell-
conditioned medium, 15% FCS, 2 mmol/L l-glutamine, 100
U/ml penicillin G, and 100 mg/ml streptomycin) (Gibco, Long
Island, NY, USA) , incubated at 37°C in 5% CO2. At day 3, new
fresh L-Cell conditioned medium was added. Monolayer of
macrophages was scrapped at day 6. Macrophages were
culture in DMEM/1% for one day before the experiments.
The monocytic cell line THP-1 was cultured in RPMI-1640
medium supplemented with 5% FCS, 100 U/mL penicillin, 100
μg/mL streptomycin, 2 mM L-glutamine, 15 mM HEPES and 11
mM sodium bicarbonate. Cell cultures were maintained in a
humidified atmosphere containing 5% CO2 at 37°C. The
differentiation of THP-1 monocytes into macrophages was
induced by 150 nM phorbol 12-myristate-13-acetate (PMA) for
24 h. Non-adherent cells were removed by aspiration of the
supernatant followed by replacement with fresh medium.
Uptake of oxLDL
LDL was labeled with Fluorescein isothiocyanate (FITC)
(Merck Chemicals, Nottingham, UK), as described
previously[17,18]. Breafly, 2 mg/mL of LDL were dialyzed in
carbonate buffer (NaHCO3 0.5 mol/L; EDTA 1 mmol/L pH 9.5)
containing 2 mg of Fluorescein isothiocyanate (FITC),
overnight at 4°C. The unbound FITC was removed by dialysis
in PBS/EDTA and PD10 column (Amersham Pharmacia
Biotech, Uppsala, Sweden). The FITC concentration in LDL
was determined by spectroscopy against FITC standard
solution at 495 nm. The F/P (fluorochrome/protein) molar ratio
was calculated and admitted in the range of 2.4 to 3 as
previously described [19]. FITC-LDL was oxidized by CuSO4 (5
μmol/L per mg of LDL protein; 18 h; 37°C). Cells were treated
with PAFR antagonists “WEB2170 (50 µmol/L) (Boehringer
Ingelheim, Pharma KG, Biberach, Germany), CV3988 (10
µmol/L) (Tocris Bioscience, Bristol, UK)” alone or in
combination with anti-CD36 blocking antibody (1 µg/mL)
(monoclonal IgA anti-CD36, clone CRF D-2712, BD
Biosciences, Franklin Lakes, NJ, USA), for 30 min, then
incubated with FITC-oxLDL (30 µg/mL) for 1 h at 37°C. In some
experiments the cells were pre-treated with the Methyl-β-
cyclodextrin (βCD) or with the inactive analogue α-ciclodextrin
(αCD) (all from Sigma-Aldrich, St. Louis, MO, USA) before
uptake assay. Cells were washed with cold PBS and fixed with
2% formaldehyde. The uptake of FITC-oxLDL was visualized
by fluorescent microscopy and evaluated in flow cytometer
(FACS Canto II - Becton BD Biosciences) and the data were
analyzed by the software Summit® V4.3 (DakoCytomation).
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Co-immunoprecipitation and immunoblotting
Macrophages were treated with oxLDL (30 µg/mL) or PAF
(10-7 mol/L) for 20 min. Resting and activated cells were lysed
without agitation on ice for 30 min using HEPES buffer
containing 1 mmol/L CaCl2, 1 mmol/L MgCl2, 1% Triton-x-100,
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA)
and phosphatase inhibitors (Calbiochem- Merck Chemicals,
Nottingham, UK). Post-nuclear lysates were incubated
overnight with the primary antibody of interest (rabbit anti-
PAFR or mouse IgA anti-CD36). Protein A-Sepharose (GE
Healthcare, NJ, USA) and protein G-Sepharose (Amersham
Pharmacia Biotech, Uppsala, Sweden) were added to samples
containing anti-PAFR and anti-CD36, respectively, and
incubated for 3 h at 4°C with gentle agitation. Immune
complexes bound to beads were washed three times with
HEPES buffer containing protease and phosphatase inhibitors,
without triton-x-100, and boiled in SDS sample buffer for 5
minutes. Proteins were separated by 10% SDS-PAGE,
transferred to a Hybond™ nitrocellulose membrane (GE
Healthcare, NJ, USA), and incubated with rabbit-anti-PAFR
(Cayman Chemical, Ann Arbor, Michigan, USA) or mouse IgA-
anti-CD36 (BD Biosciences, Franklin Lakes, NJ, USA) or with
mouse anti-flotillin-1(BD Biosciences, Franklin Lakes, NJ,
USA). As secondary antibodies we used anti-rabbit IgG-HPR
(1:2,000), anti-mouse-HRP (1:1,000) (Cell Signaling
Technology, Beverly, MA, USA), biotin-anti-IgA (1:500) (BD
Biosciences, Franklin Lakes, NJ, USA) with streptavidin-HRP
(1:200) (Life Technologies, Carlsbad, CA, USA) and visualized
using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific, Rockford, IL, USA). The resulting
autoradiograms were analyzed with the AlphaEaseFCTM
software V3.2 beta (Alpha Innotech).
Transfection of HEK 293T cells
HEK 293T cells (ATCC) were cultured in DMEM
supplemented with 10% FCS, 15 mM HEPES, 2 mmol/L L-
glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin.
The plasmids CD36-pcDNA3.2/V5-DEST, pcDNA3-kozac-
mycPAFR and the control plasmid pcDNA3 were purified using
a Qiagen Plasmid Kit (Qiagen Inc., Valencia, CA, USA). The
day before the transfection, HEK 293T cells were seeded onto
24-well plates at a density of 2 x 105 cells/well. The cells were
transiently transfected with 2 µg of total plasmid DNA per well
using Lipofectin® Transfection Reagent (Invitrogen-Life
Technologies, Carlsbad, CA, USA), according to the
manufacturer’s instructions. At 48 h after transfection, the cells
were used for the experiments.
mRNA expression
RNA was isolated using TRIzol reagents (Life Technologies,
Carlsbad, CA, USA). For the real-time reverse-transcriptase
polymerase chain reaction (PCR), cDNA was synthesized
using the RevertAidTM First Strand cDNA Synthesis Kit
(Fermentas Life Sciences, Ontario, USA), according to the
manufacturer's instructions. PCR-master mix (Power SyBr®
Green, Applied Biosystems, Warrington, UK) containing the
specific primers was then added. Primers used were: hIL-10
forward: GATCCAGTTTTACCTGGAGGAG and reverse:
CCTGAGGGTCTTCAGGTTCTC; hIL12p40 forward
TGCCCATTGAGGTCATGGTG and reverse:
CTTGGGTGGGTCAGGTTTGA, and GAPDH forward:
GAGTCAACGGATTTGGTCGT and reverse:
TTGATTTTGGAGGGATCTCG. Real-time PCR was performed
using a Stratagene Mx3005PTM QPCR System (Santa Clara,
CA, USA). Relative gene expression was calculated by the 2-
Delta Delta C(T) method, as previously described[20]. Data are
shown in fold increase related to untreated cells.
MTT assay
The mitochondrial-dependent reduction of
methylthiazolyldiphenyl-tetrazolium bromide (MTT) (Sigma-
Aldrich, St. Louis, MO, USA) to formazan insoluble crystals
was used to evaluate cell viability. Briefly, 10 µL of 5 mg/ml of
MTT in PBS were added to the cells after the treatments. After
incubation at 37°C for 2 h, 100 µL of 10% SDS in 0.01 mol/L
HCl was added to dissolve the crystals and incubated for 16 h.
The absorbance was measured in a Dynatech microplate
reader at 570 nm.
Confocal microscopy of macrophages
Macrophages (2 x 105) were plated in glass cover slips and
treated with oxLDL (30 µg/mL) or PAF (10-7 mol/L) (Cayman
Chemical, Ann Arbor, Michigan, USA) for 20 minutes, and then
washed with PBS. Cells were fixed with 3% paraformaldehyde
and blocked with 1% BSA in PBS, before incubation with
primary antibodies anti-PAFR (1:100) (Cayman Chemical, Ann
Arbor, Michigan, USA) and IgA anti-CD36 (1:100) (BD
Biosciences, Franklin Lakes, NJ, USA). FITC Donkey anti-
rabbit IgG (1:100) (BioLegend, San Diego, CA, USA),
Alexa-647 donkey anti-rabbit (1:200) (Invitrogen-Life
Technologies, Carlsbad, CA, USA) or Biotin-anti–mouse IgA
(1:200) with streptavidin-PE (1:200) (BD Biosciences, Franklin
Lakes, NJ, USA) was used as the secondary antibody. Cells
stained with secondary antibody and control antibody were
used to control for the background from each fluorophore.
Slides were mounted in Prolong® Gold anti-fade reagent with
DAPI (4,6-diamidino-2-phenylindole) (Invitrogen-Life
Technologies, Carlsbad, CA, USA). Cells were imaged on a
Zeiss LSM 510 confocal microscope using 100x oil objective at
a 60-fold magnification. Images were analyzed by Pearson’s
coefficient in JACoP (Just Another Colocalization Plugin) using
the package ImageJ 1.44p (Wayne Rasband, NIH, USA)
available in http://imagej.nih.gov/ij. Confocal images were
taken with identical settings to allow comparison of staining.
Single confocal sections of the cells were captured in
multitrack. Each set of frames from a given treatment condition
depicts a representative from at least 20 analyzed cells in three
independent experiments.
Confocal microscopy of atherosclerotic plaque tissue
Carotid artery plaques were collected from patients who
were undergoing endarterectomy. Informed written consent
was obtained from all subjects. The investigation was approved
by the Ethical Committee of Northern Stockholm and was in
agreement with institutional guidelines and the principles that
were set forth in the Declaration of Helsinki. Acetone-fixed
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sections were incubated with 5% horse serum followed by a
polyclonal rabbit anti-human PAF receptor IgG antibody at a
concentration of 25 µg/mL. Binding was detected with DyLight
594 anti rabbit IgG antibody (Vector Laboratories,
Peterborough, UK). The binding specificity was detected using
the PAF receptor blocking peptide (Cayman Chemical, Ann
Arbor, Michigan, USA) prior to incubation with the PAF receptor
IgG antibody. For double staining of the PAFR and CD36 or
CD68, a mouse anti-human CD36 (Cayman Chemical, Ann
Arbor, Michigan, USA) or a mouse anti-human CD68 (BD
Biosciences, Franklin Lakes, NJ) was used as the primary
antibody, followed by DyLight 488 anti-mouse IgG (Vector
Laboratories, Peterborough, UK). Lipid autofluorescence was
blocked with 0.03% Sudan black B (Sigma Aldrich, USA) in
70% ethanol. Nuclei were visualized with DAPI (Sigma Aldrich,
St. Louis, MO, USA), and images were captured with a Leica
TCS SP5 confocal microscope.
Cytokine measurements
IL-10 (mouse and human), mIL-12p40, and hTGFβ
concentration in the supernatants of macrophages were
measured using BD OptEIATM ELISA Set (BD Biosciences, San
Diego, CA, USA).
Statistical analysis
Data are presented as mean ± SEM. Analysis of variance
(ANOVA) and the Student-Newman-Keuls post-test were used
to evaluate the statistical significance of the differences
between three or more groups. Two-tailed unpaired Student's t-
test was used when differences between two groups were
analyzed. Significance was assumed if p < 0.05.
Results
Uptake of oxLDL and IL-10 production by macrophages
requires engagement of CD36 and PAFR
Bone marrow-derived macrophages (BMDM) were treated
with the blocking antibody to CD36 alone or in combination with
two molecularly unrelated PAFR antagonists CV3988 (10
µmol/L) or WEB2170 (50 µmol/L) for 30 min and then
incubated with FITC-oxLDL for 1 h. The concentrations of
PAFR antagonists were based on previous results from our
group[10]. We found a rapid increase in macrophage
fluorescence within 30 minutes of FITC-oxLDL addition, which
accumulates in the plasma membrane and also in intracellular
vesicles (illustrated in Figure 1A). The fluorescence intensity
was quantified as a measure of oxLDL uptake. Figure 1B
shows that the uptake was reduced by pre-treatment of
macrophages with antibodies to CD36 (62% inhibition
compared to untreated group). Pre-treatment with PAFR
antagonists (WEB2170 or CV3988) also reduced the oxLDL
uptake (42% and 61% inhibition, respectively). The
combination treatment with anti-CD36 and WEB2170 or anti-
CD36 and CV3988 further reduced the oxLDL uptake (71%
and 79% inhibition, respectively). PAFR antagonists or anti-
CD36 did not affect the cell viability, measured by MTT assay,
which was around 98% in all groups. These data show that the
uptake of oxLDL by BMDM is higher when both receptors are
functional.
Next, we investigated if PAFR and CD36 are required for
IL-10 and IL-12 production, which are cytokines involved with
macrophage suppression or activation, respectively. BMDM
were pre-treated with the anti-CD36 blocking antibody alone, or
in combination with the PAFR antagonists 30 min before
stimulation with oxLDL (30 µg/mL). Under these experimental
conditions, BMDM produced IL-10 (Figure 1C), but IL-12 was
not detected (data not shown). The IL-10 production was
significantly reduced by the previous treatment of macrophages
with PAFR antagonists, an anti-CD36 blocking antibody, or a
combination of PAFR antagonists with anti-CD36. These data
show that oxLDL induces IL-10 and not IL-12, and that a
crosstalk or synergistic effect between CD36 and PAFR is
required for IL-10 production. This was further confirmed in
HEK293T cells transiently transfected with plasmids encoding
hPAFR cDNA or hCD36 cDNA, or both, and then stimulated
with oxLDL for 5 h. We found that only double transfected cells
expressed IL-10 mRNA and trace amounts of IL-12 mRNA.
Non-transfected or single transfected HEK293T cells were
unable to respond to oxLDL (Figure 1D).
The effects of oxLDL may vary according to the degree of
oxidation. We then assayed the effect of minimally oxidized
LDL (moxLDL) on IL-10 and TGFβ production by human
macrophage THP-1 cells. The moxLDL was characterized as
presenting low values for both negative charges and TBARS
compared to oxLDL, as described in methods section. The
moxLDL preparation did not induce IL-10 and TGF-β
production as did the cells stimulated with oxLDL (Figure 1E-
F).
Lipid Raft integrity is important for uptake of FITC-
oxLDL and IL-10 production.  Cholesterol-rich microdomains,
known as lipid rafts, have been shown to function as
specialized platforms for receptor interactions[21]. We,
therefore, examined whether lipid raft integrity is required for
FITC-oxLDL uptake and the induction of IL-10. Macrophages
were treated with methyl-β-cyclodextrin (βCD), a synthetic
molecule that sequesters cholesterol from plasma membranes
and disrupts lipid rafts. We found that βCD caused a significant
reduction (70%) in FITC-oxLDL uptake (Figure 2A and 2B). In
Figure 2C it can be seen that βCD treatment markedly inhibited
the production of IL-10 induced by oxLDL. The inactive analog
αCD did not affect the IL-10 production. These data show that
the lipid raft integrity is important for the oxLDL uptake and
IL-10 production induced by oxLDL.
It has been shown that Syk (Spleen tyrosine kinase) may
interact with CD36 in the lipid raft fraction, contributing to its
association with other receptors and adaptor proteins and
allowing it to drive cell activation [22]. To investigate the role of
Syk we treated macrophages with a Syk-selective inhibitor,
piceatannol (20 µmol/L) or with a general kinase inhibitor
genistein (10 µmol/L), 10 min before the FITC-oxLDL uptake
assay or oxLDL-induced IL-10 production. We found that
piceatannol did not interfere with the oxLDL uptake or IL-10
production (Table 1). In contrast, genistein treatment
decreased both FITC-oxLDL uptake and IL-10 production.
These results show that oxLDL uptake and IL-10 production is
oxLDL Induces PAFR-CD36 Recruitment in Lipid Rafts
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Figure 1.  CD36 and PAFR cooperatively mediate the uptake of oxLDL and IL-10 production.  Macrophages were treated with
mAb to CD36 (1:500) alone or in combination with WEB2170 (50 µmol/L) or CV3988 (10 μmol/L) for 30 min and then incubated with
FITC-oxLDL for 1 h. In (A-B) The uptake was visualized in confocal microscopy and measured by FACS (B). In (C), after treatment,
cells were stimulated with oxLDL (30 µg/mL) and the IL-10 production was evaluated after 24 h by ELISA. Data are presented as
mean ± SEM of the mean fluorescence Intensity (MFI). ***p<0.001 comparing with non-stimulated cells. # p<0.05 comparing cells
treated with non-treated cells. In (D) HEK 293T cells were transiently transfected with hCD36 and/or hPAFR and stimulated with
oxLDL (30 µg/mL). The mRNA expression for IL-10 and IL-12 was evaluated after 5 h. *** p<0.001; * p<0.05 comparing with cDNA3
plasmid control transfected cells. In (E-F), THP-1 monocytes were differentiated into macrophages with PMA, followed by treatment
with LDL, moxLDL or oxLDL (30 µg/mL) for 24 h. IL-10 and TGFβ were measured in the supernatant were measured by ELISA.
*p<0.05 comparing with non-stimulated cells.
doi: 10.1371/journal.pone.0076893.g001
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dependent on the activation of kinases other than Syk. The
treatments employed in these studies did not affect the cell
viability, measured by MTT assay.
oxLDL induces colocalization and co-
immunoprecipitation of PAFR and CD36
In order to investigate whether oxLDL induces a complex
formation with PAFR and CD36, we performed co-
immunoprecipitation assays. Macrophages were stimulated
with oxLDL (30 µg/mL) or PAF (10-7 mol/L) for 20 min. PAFR
and CD36 from the cell lysate were immunoprecipitated as
described in the methods section. Figure 3A shows that
stimulation with oxLDL rapidly induced receptor interaction,
which was detected by the co-immunoprecipitation of PAFR
and CD36 (2-fold increase compared to non-stimulated
control). In non-stimulated control cells we detected a small
proportion of PAFR co-immunoprecipitated with CD36, which
was not significantly increased by PAF stimulation. Next, we
analyzed the immunoprecipitation of PAFR or CD36 with
flotillin-1, a lipid raft associated protein[23]. It can be seen in
Figure 3B that oxLDL induced the strong co-
Table 1. Syk activation is not required for IL-10 production
and oxLDL uptake by macrophages.
 IL-10 (pg/mL) oxLDL uptake (MFI)
Cont 52.6 ± 11 7.8 ± 1
oxLDL 221.1 ± 49 *** 97.5 ± 8 ***
oxLDL + Piceat 354.8 ± 80 104.5 ± 2
oxLDL + Genist 43.4 ± 8 # 50.4 ± 17 #
Macrophages were treated with the Syk-selective inhibitor, piceatannol (20
µmol/L), or with a general kinase inhibitor genistein (10 µmol/L), 10 min. For
uptake assay, treated cells were incubated with FITC-oxLDL for 1 h and the
fluorescence measured by FACS. Data are presented in mean of fluorescence
intensity (MFI) For IL-10 production, treated cells were stimulated with oxLDL (30
µg/mL) for 24 h and the cytokine production was evaluated in the supernatants.
Data are presented as mean ± SEM of three independent experiments. ***p<0.001
comparing with non-stimulated cells. # p<0.05 comparing cells treated with non-
treated cells.
doi: 10.1371/journal.pone.0076893.t001
Figure 2.  Lipid raft integrity is important for oxLDL uptake and IL-10 production.  Macrophages were treated with βCD (2
mmol/L) or with the inactive analog αCD for 5 min. The uptake assay was performed by incubation with FITC-oxLDL (30 µg/mL) for
1 h and visualized by microscopy. Data are presented as representative Figure (A). The fluorescence was quantified by the
AlphaEaseFC™ software V3.2 beta (Alpha Innotech) (B). IL-10 production was measured in the supernatants after oxLDL
stimulation for 24 h (C). Graph Data are presented as mean ± SEM. ***p<0.001 comparing with non-stimulated cells. #p<0.05
comparing βCD treated with non-treated cells.
doi: 10.1371/journal.pone.0076893.g002
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immunoprecipitation of flotillin-1with PAFR and CD36 (around
1.8-fold increase in relation to non-stimulated cells). These
results strongly suggest that PAFR and CD36 associate in a
protein complex induced when oxLDL is added to
macrophages and this may occur in the lipid raft platforms. To
further define the association of PAFR and CD36, we
performed colocalization assays by confocal microscopy.
BMDM were stimulated with oxLDL (30 µg/mL) for 5, 10 and 20
min, fixed with 3% paraformaldehyde and labeled with
antibodies to CD36 and PAFR. We found that oxLDL
stimulation induced a redistribution of PAFR and CD36 in
macrophages increasing the colocalization on the macrophage
membrane (Figure 4A). This effect was time-dependent, with
maximum colocalization seen in 10 min (Figure 4B). In
contrast, in PAF stimulated macrophages, only a discrete
receptor colocalization was observed. These data indicate that
oxLDL induces a spatial redistribution in the plasma
membrane, resulting in the recruitment of PAFR and CD36 to
the same complex in macrophages.
oxLDL induces colocalization of GM1 ganglioside with
PAFR and CD36
As flotilin-1 has immunoprecipitated with CD36 and PAFR
after oxLDL stimulation (Figure 3B), we next investigated
whether GM1, another constitutive raft protein used as a raft
marker, colocalizes with PAFR and CD36 in macrophages
Figure 3.  oxLDL induces co-immunoprecipitation of CD36-PAFR-Flotillin-1.  Macrophages were treated with oxLDL (30
μg/mL) or PAF (10-7 mol/L) for 20 min at 37°C prior addition of the lysis buffer. Cell lysates were subjected to immunoprecipitating
and immunoblotting as described in “Methods section” using antibodies to CD36, PAFR (A) and Flotillin-1 (B). Protein expression
was quantified by the AlphaEaseFC™ software V3.2 beta (Alpha Innotech). The autoradiographs show one representative
experiment and Graph data are presented as mean ± SEM of four experiments. In A, western blot figures were obtained from the
same gel. ** p<0.01 comparing oxLDL-stimulated with the non-stimulated cells (dashed lines).
doi: 10.1371/journal.pone.0076893.g003
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stimulated with oxLDL. GM1 was cross-linked by CTxB, and
anti-CTxB antibody detected clustering (patching) of GM1.
Utilizing Ctx-FITC staining, GM1 was visualized in a diffuse
distribution in resting macrophages and clustering in oxLDL-
stimulated macrophages (Figure 5A). Confocal microscopy
indicated that a small proportion of CD36 colocalized with GM1
in resting cells, whereas PAFR was not detected in these
areas. The oxLDL treatment for 10 minutes increased the
colocalization of both PAFR and CD36 with GM1 (Figure 5B
and 5C). In experiments using triple staining, we found that
oxLDL rapidly induces the recruitment of PAFR and CD36 to
the same lipid raft (Figure 6D). These experiments confirm the
data obtained with co-immunoprecipation and cholesterol
depletion, showing that oxLDL induces the recruitment of
PAFR and CD36 to the same lipid raft membrane platforms.
Figure 4.  oxLDL induces colocalizaton of CD36 and PAFR.  Macrophages stimulated with oxLDL (30 μg/mL) or PAF (10-7 mol/L)
for 10 min, before staining for PAFR-FITC (green) and CD36-PE (red) and visualized by confocal microcopy (A). Graph data shows
the colocalization of PAFR and CD36 in macrophages stimulated with oxLDL for 5, 10 and 20 min (B). Colocalization images were
quantified using the package ImageJ 1.44p and Graph data are presented as mean ± SEM of 15 pictures in three independent
experiments. ** p<0.01 comparing oxLDL-stimulated with the non-stimulated cells. Images are representative of at least three
independent experiments. Yellow patches signify areas of colocalization of CD36 and PAFR.
doi: 10.1371/journal.pone.0076893.g004
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Colocalization of PAFR and CD36 in human
atherosclerotic plaques
Next, we investigated whether the colocalization of both
receptors is present in atherosclerotic lesions. Human carotid
atherosclerotic lesions were labeled with antibodies to hPAFR
and hCD36. The specificity of the anti-hPAFR was confirmed
by competitive assay using the PAF receptor blocking peptide
(Figure 6A). Figure 6B shows that PAFR was predominantly
colocalized with CD68 positive cells indicating its expression in
macrophages. Consistent with results found in mouse
macrophages, PAFR colocalized with CD36 in human
atherosclerotic plaque (Figure 6B). These results show that
PAFR and CD36 act cooperatively in human cells and this may
be relevant in atherosclerosis development.
Figure 5.  oxLDL induces colocalization of CD36 and PAFR in lipid raft microdomains.  Macrophages were stimulated with
oxLDL (30 µg/mL) for 10 minutes. Cells were fixed and stained with CTxB-Alexa 488/anti-CTxB, Alexa-647 anti-PAFR, and
phycoerythrin anti-CD36, as described in the methods section. Colocalization was visualized by confocal microcopy at a 60-fold
magnification. In A-B, macrophages were stimulated with oxLDL and stained for GM1 lipid raft fraction (green) alone or in
combination with PAFR-Alexa-647 (red) or CD36-PE (red). Yellow patches signify areas of colocalization of PAFR or CD36 and
GM1. In (C), colocalization images were quantified using the package ImageJ 1.44p and Graph data are presented as mean ± SEM
of 10-15 pictures in three independent experiments. Dashed lines signify the non-stimulated cells. In (D), macrophages were triple
stained for GM1- Alexa 488 (green), PAFR – Alexa 647(blue) and CD36-PE (red). Colocalization areas of triple stained are
visualized in white/gray patches.
doi: 10.1371/journal.pone.0076893.g005
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Discussion
Here we describe that PAFR and CD36 are recruited to the
same complex and this is required for an optimal oxLDL uptake
and IL-10 production induced by oxLDL in macrophages. This
was confirmed by transfection experiments where oxLDL
induced the expression of IL-10 mRNA only in HEK293T
expressing both receptors. The disruption of lipid rafts by
Figure 6.  CD36-PAFR complex is present in human carotid plaques.  Frozen sections of human carotid plaques were fixed with
acetone and stained with rabbit and with the mouse anti-human CD36 or mouse anti-human CD68. Anti-rabbit IgG DyLight-594 or
anti-mouse DyLight-488 were used as a secondary antibody. Colocalization was visualized by confocal microcopy at a 60-fold
magnification. In (A), the specificity of anti-PAFR was evaluated by pre-treatment with PAF receptor blocking peptide and after
stained for hPAFR. In (B) is shown double staining of PAFR with CD36 or with CD68. Yellow patches signify areas of colocalization.
Figures in (A) were used as staining control and were acquired in different magnification.
doi: 10.1371/journal.pone.0076893.g006
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treatment with mβCD reduced IL-10 production. The uptake of
oxLDL was increased when both receptors were present. The
interaction between these receptors seems to require lipid rafts
formation. Finally, we observed that PAFR and CD36 are
colocalized in human atherosclerotic plaques.
In a previous work we found that PAFR-antagonists reduce
oxLDL uptake and that PAFR deficient mice take up less
oxLDL than their littermate controls[10]. Thus, we already
suspected that CD36 and PAFR interact upon macrophage
exposure to oxLDL. Here, we show that PAFR antagonists and
mAb to CD36 alone or in combination reduced the oxLDL
uptake. Results were consistent using two different and
molecularly unrelated PAFR antagonists that induced similar
inhibition.
CD36 is considered a pattern recognition receptor that binds
to negatively charged ligands from both pathogens and
oxidized/damaged self-components[24,25]. This receptor was
shown to interact with TLR2-TLR6 in macrophages exposed to
S. aureus-derived lipoteicoic acid (LTR)[26] and also with
TLR4-TLR6 in cells stimulated with amyloid-β protein[13]. It is
known that CD36 recognizes oxidized phospholipids and
apoptotic cells[25]. We have shown that PAFR also recognizes
apoptotic cells and oxLDL and suggested that these receptors
interact somehow in macrophages membrane for optimal
oxLDL uptake[10,27].
According the oxidative stage, the LDL might have similar or
different effects on cell activation. A minimal oxidation degree
of LDL is characterized by antioxidant depletion, oxidation of
arachidonic acid-containing phospholipids, relatively low
linoleic acid oxidation and insignificant protein modifications
[28]. However, in highly oxidized LDL, phospholipids,
triacylglycerol and cholesterol esters are transformed into
hydroperoxides which react with ApoB-100, resulting in
modification and fragmentation of amino acid side chains
[29,30]. Here, we found that only the LDL with a high degree of
oxidation increased IL-10 and TGF-β production in human
THP-1 cells. However, in previous study we showed that LDL
with low and high oxidation both increase the expression of
CD36 and may both contribute to foam cell formation [31].
Recognition of oxLDL by murine macrophage receptors
induces the production of IL-10 but not IL-12. Our results show
that both CD36 and PAFR are involved in IL-10 production.
Although several receptors can be involved in oxLDL
recognition [32], the oxLDL-induced IL-10 production depends
mainly on CD36 and PAFR since, in the present study, the
production of this cytokine was almost completely blocked by
treatment with PAFR antagonists and mAb to CD36. Our
results show that IL-10 production by BMDM is dependent on
PAFR activation corroborating previous results reported by
Verouti et al, 2011[33] . These authors showed that oxLDL
induced MCP-1 production partly through PAFR activation and
that this occurred via protein kinases activation. Our previous
results are also in accordance with these authors, since we
showed that oxLDL-induced IL-8 production by human
monocytes-macrophages was dependent on MAPK and
PI3K/AKT pathways activation [11]. It was also reported that
the activation of PAFR is essential for oxLDL-induced
recruitment of human bone marrow-derived mesenchymal stem
cells dependent on MAPK activation [34].
IL-10 is an anti-inflammatory cytokine that was found to be
expressed by macrophages from atherosclerosclerotic
plaques[35]. This cytokine is a marker of alternatively activated
macrophages which are involved in repair mechanisms with
fibroblasts activation and collagen production[35]. IL-10 was
shown to decreases CD36 mRNA expression and increases
the cholesterol efflux in macrophages[36]. Other studies have
shown that IL-10 induces lipid accumulation in macrophages
and may contribute to the foam cell formation[37]. However, its
role in atherosclerosis still remains to be determined.
Here, we demonstrate that the lipid rafts disruption
decreases the uptake of oxLDL and IL-10 production by
macrophages. Lipid rafts are cholesterol-rich and
sphingomyelin-rich membrane domains functioning as scaffold
platforms for the association of signaling molecules and
compartmentalization of cellular processes. It has also been
shown that lipid raft formation is involved in cell activation
induced by oxidized lipids[38], production of pro-inflammatory
cytokines[39] and uptake of acetyl LDL[40]. The following
results indicate that the interaction of CD36 and PAFR occurs
within lipid raft domains of the BMDM membrane: a) Disruption
of lipid rafts by treatment with MβCD reduced the oxLDL
uptake and IL-10 production; b) oxLDL induced co-
immunoprecipitation of PAFR and CD36 with the constitutive
raft protein, flotillin-1[23] and colocalization of PAFR and CD36
with the lipid raft marker GM1-ganglioside[41]. Data presented
by others have been shown that CD36 is recruited to lipid rafts
in a ligand-dependent manner[22,42]. Although PAFR is a
GPCR and might interact within lipid raft platforms[43], there is
only one study showing that PAFR migrates to lipid rafts, which
was observed in cells transfected with PAFR and stimulated
with PAF[15]. In a previous study we showed that both
receptors, PAFR and CD36, are able to bind the oxLDL.
However, only the co-stimulation of CD36 and PAFR by oxLDL
was able to transduce intracellular signaling for cytokine
production [11]. Although our data clearly suggest a crosstalk
between receptors for PAF and CD36, they do not show at
what level the interaction among these receptors occurs. We
show here that one possibility is that oxLDL recruits both
receptors to specific membrane microdomains (lipid rafts),
allowing association between these two receptors. However,
we cannot exclude the possibility that they signal in parallel,
interacting downstream or that other receptors that are
recruited to the same microenvironment also contribute.
The signaling elicited by CD36 engagement leads to the
recruitment of the adaptor protein Syk, which was shown to
contribute to receptors association[22]. In our study, Syk
inhibition did not affect oxLDL uptake or IL-10 production, in
contrast to genistein, a general inhibitor of kinases, which
reduced both events. This indicates that Syk is not involved in
CD36-PAFR interaction induced by oxLDL. It has been shown
that Syk phosphorylation requires macrophage activation
induced by LDL with minimal modification[44]. It is likely that
oxLDL will induce distinct effects depending on the degree of
oxidation. Indeed, previous data showed that LDL with high or
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low degrees of oxidation has different effects on
macrophage[31].
The CD36 and PAFR complex formation in human
atherosclerotic plaques is intriguing. It can be speculated that
these receptors association would contribute not only to
increased foam cell formation but also contributes to chronic
inflammatory response in the atherosclerotic plaque. However,
we have no clues as to how this affects the progression of
atherosclerosis. Although the role of PAF/CD36 complex
formation in atherosclerotic plaques remains to be determined,
this study increases our understanding of macrophage
interactions with oxLDL and provides new insights into
atherosclerosis research.
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